

Attorney docket number: HTS-0008US.P1

AMENDMENTS TO THE CLAIMS

Claims 1-13. (canceled)

14. (currently amended) A compound ~~of claim 1~~ wherein the compound comprises 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding forkhead box O1A, wherein the compound is at least 70% complementary to said nucleic acid molecule, wherein the compound inhibits the expression of said nucleic acid molecule, and wherein the compound comprises the nucleobase sequence of SEQ ID NO: 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 33, 34, 35, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 51, 52, 54, 86, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 172, 173, 174, 175, or 176.
15. (currently amended) A compound ~~of claim 1~~ wherein the compound comprises 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding forkhead box O1A, wherein the compound is at least 70% complementary to said nucleic acid molecule, wherein the compound inhibits the expression of said nucleic acid molecule, and wherein the compound comprises at least 8 consecutive nucleobases of SEQ ID NO: 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 33, 34, 35, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 51, 52, 54, 86, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 172, 173, 174, 175, or 176.

Claims 16-18. (canceled)

19. (currently amended) A compound of claim ~~1-14~~ which is an antisense oligonucleotide.
20. (original) A compound of claim 19 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
21. (original) A compound of claim 20 wherein the modified internucleoside linkage is a phosphorothioate linkage.
22. (original) A compound of claim 19 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Attorney docket number: HTS-0008US.P1

23. (original) A compound of claim 22 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
24. (original) A compound of claim 19 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
25. (original) A compound of claim 24 wherein the modified nucleobase is a 5-methylcytosine.
26. (original) A compound of claim 19 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
27. (currently amended) A composition comprising the compound of claim ~~1~~14 and a pharmaceutically acceptable carrier or diluent.
28. (original) A composition of claim 27 further comprising a colloidal dispersion system.
29. (original) A composition of claim 27 wherein the compound is an antisense oligonucleotide.
30. (withdrawn) A method of decreasing the expression of forkhead box O1A in cells or tissues comprising contacting the cells or tissues with a compound of claim 1 so that expression of forkhead box O1A is decreased.
31. (withdrawn) A method of claim of claim 30 wherein ghte tissues or cells is liver or fat tissue or cells.
32. (withdrawn) A method of treating an animal having a disease or condition associated with forkhead box O1A comprising administering to the animal a therapeutically or prophylactically effective amount of a compound of claim 1 so that expression of forkhead box O1A is decreased.
33. (withdrawn) A method of claim 32 whercin the disease or condition is a hyperproliferative disorder.
34. (withdrawn) A method of claim 33 wherein the hyperproliferative disorder is cancer.
35. (withdrawn) A method of claim 34 wherein the cancer is rhabdomyosarcoma.
36. (withdrawn) A method of claim 32 wherein the disease or condition is diabetes.
37. (withdrawn) A method of claim 36 wherein the diabetes is type 2.

Attorney docket number: HTS-0008US.P1

Claim 38. (canceled)

39. (withdrawn) A method of decreasing blood or plasma glucose in an animal comprising administering to the animal a therapeutically or prophylactically effective amount of a compound of claim 1 so that expression of forkhead box O1A is decreased.
40. (withdrawn) A method of improving glucose tolerance in an animal comprising administering to the animal a therapeutically or prophylactically effective amount of a compound of claim 1 so that expression of forkhead box O1A is decreased.
41. (withdrawn) A method of normalizing insulin levels in an animal comprising administering to said animal a therapeutically or prophylactically effective amount of a compound of claim 1 so that expression of forkhead O1A is decreased.
42. (new) A compound 15 to 30 nucleobases in length comprising at least 8 consecutive nucleobases of SEQ ID NO: 172.
43. (new) A compound of claim 42 wherein the compound is at least 70% complementary to a nucleic acid molecule encoding forkhead box O1A.
44. (new) A compound of claim 42 wherein the compound is at least 80% complementary to a nucleic acid molecule encoding forkhead box O1A.
45. (new) A compound of claim 42 wherein the compound is at least 90% complementary to a nucleic acid molecule encoding forkhead box O1A.
46. (new) A compound of claim 42 wherein the compound is at least 95% complementary to a nucleic acid molecule encoding forkhead box O1A.
47. (new) A compound of claim 42 wherein said compound is 20 nucleobases in length.
48. (new) A compound 20 nucleobases in length comprising the nucleobase sequence of SEQ ID NO: 172.
49. (new) The compound of claim 48 further comprising at least one modified internucleoside linkage or at least one modified sugar moiety.
50. (new) The compound of claim 48 further comprising at least one 2'-O-methoxyethyl sugar moiety.

Attorney docket number: HTS-0008US.P1

51. (new) The compound of claim 48 characterized by a ten deoxynucleotide gap flanked on its 5' and 3' ends with 5' 2'-O-methoxyethyl nucleotides.
52. (new) The compound of claim 51 wherein each internucleoside linkage is a phosphorothioate linkage.
53. (new) The compound of claim 51 wherein each cytosine is a 5-methylcytosine.